Medical industry has $40B impact

San Antonio’s health care and bioscience industry accounted for $40.2 billion in sales of products ...

Study shows stress hormone’s link to memory deficits, brain shrinkage

Dr. Sudha Seshadri was the senior author on the study. Courtesy Photo By Lauren Caruba, San Antonio ...

StemBioSys Names Burzik as Chair, Hutchens as CEO
August 27, 2014

Cathy Burzik and Bob Hutchens

SAN ANTONIO - StemBioSys, Inc., (SBS) a privately-held, San Antonio-based biomedical company focused on stem cell-based products and therapies, has named Catherine M. Burzik as Board Chair and Robert A. Hutchens, as President and Chief Executive Officer.

Burzik formerly served as President, CEO and Director of Kinetic Concepts, Inc., a leading medical device and regenerative medicine company based in San Antonio. She has been an advisor to SBS since early 2012 and is currently a general partner in Targeted Technologies, an early stage venture capital firm concentrating on medical device, life sciences and biotech investments. Targeted Technologies was the lead investor in the recent Series A capital raise for SBS. Burzik serves on the boards of numerous companies and nonprofit organizations, among them medical technology giant Becton, Dickinson and Company (NYSE:BDX), several Targeted Technologies portfolio companies, the San Antonio Branch of the Dallas Federal Reserve Board and the Tobin Center for the Performing Arts.

Hutchens comes to StemBioSys having spent 20 years in accounting, finance and executive roles for several companies and firms, most recently 11 years as a partner with the international consulting firm Booz & Company in New York, where he played a key role in the firm's health care practice, both in the U.S. and Europe. For Booz & Company, Hutchens worked on engagements with pharmaceutical and medical device manufacturers, as well as projects with the Centers for Disease Control (CDC) and on bio terrorism defense efforts.

Burzik succeeds StemBioSys Founder Steven A. Davis, MD, as Chair while Hutchens moves into the CEO position on a full-time basis, following interim CEO John W. Feik who had served in that capacity since May of this year. Davis and Feik both remain as directors of StemBioSys.

"It is a real coup for us, as a young company, to be able to secure Cathy Burzik and Bob Hutchens for these two key positions," Davis said. "They bring extraordinary leadership and industry experience to StemBioSys at this critical stage of our development. Their involvement speaks volumes about the confidence they have in the potential of the company's patented and proprietary stem cell technology platforms."

Burzik said, "StemBioSys has very promising proprietary life science products which will accelerate research and therapy development in the rapidly growing field of stem cell-based regenerative medicine. Dr. Davis saw that potential early-on and built the company around that science and technology. Our early-stage venture fund, Targeted Technologies, is highly encouraged with the progress that SBS is making in both research and product development. We look forward to product commercialization within the next year."

"Bob Hutchens sees that future, too," she said, "and, we are thrilled to have his talent and experience on board as our President and CEO. He will be here in San Antonio and we are looking forward to executing the strategies he develops for our next phase of corporate development."

Hutchens said, "There's no question that StemBioSys can achieve a leadership role in this industry, and that's why I was eager to come here and join the team. We are in the right industry - regenerative medicine and stem cells - and StemBioSys is creating the tools that can position us to take advantage of the growth opportunities that are rapidly developing."About StemBioSys, Inc.


About StemBioSys, Inc.
StemBioSys, Inc., a privately held, San Antonio-based biomedical company, manufactures and develops innovative, advanced stem cell technologies to meet the promise of regenerative medicine in a surging global market. Its patented and proprietary technology platforms -- licensed from the University of Texas Board of Regents -- overcome key obstacles to creating clinically useful stem cell therapies.

StemBioSys, Inc. Media Contact

Sy Griffey, PhD., Chief Operating Officer



Stay informed. Subscribe to BioMed SA news alerts.